Benzinga
29 Jun 2026, 06:34 UTC · 19w ago
Impact · against what's priced in
Viridian Therapeutics and Universe Pharmaceuticals are seeing positive catalysts from FDA approval and M&A respectively, while Lantheus faces a setback with a CRL. Concentrix and AeroVironment remain speculative as they await earnings reports.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Viridian Therapeutics Inc. (VRDN) received FDA approval and launched Lumvoa for the treatment of thyroid eye disease.
So whatFDA approval and commercial launch of a new drug is a major catalyst for revenue growth and valuation in biotech.
More positive than 93% of claims this week
Lantheus Holdings Inc. (LNTH) received a Complete Response Letter (CRL) from the FDA regarding its new drug application for LNTH-2501.
Continue reading
5 related stories
FDA approval and the launch of Lumvoa for thyroid eye disease provide a direct path to revenue growth.
Read from the article alone
No priced-in read yet
The receipt of a Complete Response Letter for LNTH-2501 delays potential approval and market entry.
Read from the article alone
No priced-in read yet
While shares rose 11% in anticipation, the catalyst is pending the actual earnings release after the closing bell.
Read from the article alone
Scored by the NIS engine · methodology.
More negative than 88% of claims this week
Universe Pharmaceuticals Inc. (UPC) will acquire Best Praise International for $10.75 million.
More positive than 64% of claims this week
Concentrix Corp. (CNXC) and AeroVironment Inc. (AVAV) are scheduled to report quarterly earnings after the closing bell.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Shares jumped 10.7% following FDA approval and launch of Lumvoa.
More negative than 86% of ticker scores this week
The FDA issued a Complete Response Letter regarding a new drug application, indicating a setback.
More positive than 69% of ticker scores this week
Shares jumped 11% on Friday ahead of quarterly earnings expectations.
More positive than 63% of ticker scores this week
Shares gained 4.2% following the announcement of an acquisition of Best Praise International.
More positive than 56% of ticker scores this week
Shares gained 0.9% on Friday heading into their earnings release.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
+70.3%
Price agrees with the score
$30.48 vs $17.90 close before publication (Jun 26) · not market-adjusted
VRDN chart →−7.8%
Price agrees with the score
$101.25 vs $109.80 close before publication (Jun 26) · not market-adjusted
LNTH chart →+27.9%
Price agrees with the score
$31.97 vs $25.00 close before publication (Jun 26) · not market-adjusted
CNXC chart →
